Literature DB >> 19179199

Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.

Bimal Shah1, Adrian F Hernandez, Li Liang, Sana M Al-Khatib, Clyde W Yancy, Gregg C Fonarow, Eric D Peterson.   

Abstract

OBJECTIVES: The aim of this study was to describe hospital variation and factors associated with adherence to guidelines for implantable cardioverter-defibrillator (ICD) therapy.
BACKGROUND: Studies have shown incomplete application of ICD therapy in eligible heart failure (HF) patients.
METHODS: New or discharge prescription rates for ICD therapy (ejection fraction <or=30% without documented ICD contraindications) for hospitals were calculated from participants in the GWTG-HF (Get With The Guidelines-Heart Failure) registry during January 2005 to June 2007. With hierarchical modeling, hospitals' patient case-mix adjusted ICD rate and hospital factors associated with ICD use were determined. The association of ICD rate and other quality of care indicators and procedure use was determined.
RESULTS: Overall use of ICD in-hospital or planned implantation rate was 20%. This rate ranged widely among hospitals, from 1% among the lowest tertile to 35% among the top tertile (p < 0.01). After adjusting for patient case mix, independent hospital characteristics associated with higher ICD use were percutaneous coronary intervention, coronary artery bypass grafting, and heart transplant capability as well as larger hospital bed size (p < 0.01). Hospital Centers for Medicare and Medicaid Services/Joint Commission on the Accreditation of Healthcare Organizations performance measures (discharge instructions, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use, smoking cessation; p >or= 0.05) were similar across ICD, whereas higher ICD-rate hospitals had higher adherence to GWTG-HF performance measures (beta-blocker use, evidence-based beta-blocker use, aldosterone-antagonist, hydralazine/nitrate; p < 0.05) except warfarin in patients with atrial fibrillation (p = 0.18).
CONCLUSIONS: There is significant unexplained hospital variation in the use of ICD therapy among potentially eligible HF patients. However, hospitals that use ICD therapy more often also have more rapidly adopted other newer evidence-based HF therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19179199     DOI: 10.1016/j.jacc.2008.09.045

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  30 in total

Review 1.  Heart failure in women.

Authors:  J Julia Shin; Eman Hamad; Sandhya Murthy; Ileana L Piña
Journal:  Clin Cardiol       Date:  2012-03       Impact factor: 2.882

Review 2.  [Is "evidence-based medicine" followed by "confidence-based medicine"?].

Authors:  Franz Porzsolt; Heiner Fangerau
Journal:  Med Klin (Munich)       Date:  2010-09-08

3.  Definition of performance metrics and methods for screening for sudden cardiac arrest risk at a tertiary care medical center.

Authors:  Robert F Rea; Douglas Beinborn; Tracy Webster; Nancy Acker; Tammy Kester; David L Hayes; Mark McConnell
Journal:  J Interv Card Electrophysiol       Date:  2011-04-14       Impact factor: 1.900

4.  Utilization rates of implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: a 2012 calculation for a midwestern health referral region.

Authors:  Allen Hoang; Changyu Shen; James Zheng; Stanley Taylor; William J Groh; Marc Rosenman; Alfred E Buxton; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2014-02-22       Impact factor: 6.343

Review 5.  Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium.

Authors:  Daniel B Kramer; Daniel D Matlock; Alfred E Buxton; Nathan E Goldstein; Carol Goodwin; Ariel R Green; James N Kirkpatrick; Christopher Knoepke; Rachel Lampert; Paul S Mueller; Matthew R Reynolds; John A Spertus; Lynne W Stevenson; Susan L Mitchell
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2015-06-02

6.  Association Between Treatment by Locum Tenens Internal Medicine Physicians and 30-Day Mortality Among Hospitalized Medicare Beneficiaries.

Authors:  Daniel M Blumenthal; Andrew R Olenski; Yusuke Tsugawa; Anupam B Jena
Journal:  JAMA       Date:  2017-12-05       Impact factor: 56.272

7.  Failure to reassess ejection fraction after acute myocardial infarction in potential implantable cardioverter/defibrillator candidates: insights from the Translational Research Investigating Underlying disparities in acute Myocardial infarction Patients' Health Status (TRIUMPH) registry.

Authors:  Amy Leigh Miller; Kensey Gosch; Stacie L Daugherty; Saif Rathore; Pamela N Peterson; Eric D Peterson; P Michael Ho; Paul S Chan; David E Lanfear; John A Spertus; Tracy Y Wang
Journal:  Am Heart J       Date:  2013-09-05       Impact factor: 4.749

8.  Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation.

Authors:  Nancy Luo; Haolin Xu; Hani Jneid; Gregg C Fonarow; Renato D Lopes; Jonathan P Piccini; Anne B Curtis; Andrea M Russo; William R Lewis; Roland A Matsouaka; Christopher B Granger; Robert J Mentz; Sana M Al-Khatib
Journal:  Circ Heart Fail       Date:  2018-10       Impact factor: 8.790

9.  Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.

Authors:  Paul L Hess; Melissa A Greiner; Gregg C Fonarow; Winslow Klaskala; Roger M Mills; Soko Setoguchi; Sana M Al-Khatib; Adrian F Hernandez; Lesley H Curtis
Journal:  Clin Cardiol       Date:  2012-10-15       Impact factor: 2.882

10.  Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials.

Authors:  Srinivas R Bapoje; Amit Bahia; John E Hokanson; Pamela N Peterson; Paul A Heidenreich; Joann Lindenfeld; Larry A Allen; Frederick A Masoudi
Journal:  Circ Heart Fail       Date:  2013-02-12       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.